Search Results - "Díaz Redondo, T"

Teaching basic life support to the general population. Alumni intervention analysis by Díaz-Castellanos, M A, Fernández-Carmona, A, Díaz-Redondo, A, Cárdenas-Cruz, A, García-del Moral, R, Martín-Lopez, J, Díaz-Redondo, T

“…The aim of this study was to investigate the rate at which the alumni of basic life support courses witnessed and intervened in out-of-hospital emergency…”
Get more information

Enseñando soporte vital básico a la población general. Análisis de las intervenciones de los alumnos by Díaz-Castellanos, M.A, Fernández-Carmona, A, Díaz-Redondo, A, Cárdenas-Cruz, A, García-del Moral, R, Martín-Lopez, J, Díaz-Redondo, T

“…Resumen Objetivos Estudiar la tasa de detección e intervención en situaciones de urgencia extrahospitalaria por parte de los alumnos de cursos de soporte vital…”
Get full text

Abstract P3-10-03: Different pCR rates according PAM50 defined subtypes in HER2 positive early breast cancer treated with neoadjuvant pertuzumab and trastuzumab by Díaz-Redondo, T, Lavado-Valenzuela, R, Ribelles, N, Pascual, T, Galvez, F, Falcón, A, Alamo, MC, Morales, C, Amerigo, M, Prat, A, Alba, E

“…BACKGROUND We aim to compare the benefit of adding pertuzumab (P) to the standard neoadjuvant treatment with trastuzumab (T) in patients (pt) with early…”
Get full text

Effectiveness of olaparib plus trastuzumab in HER2[+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study by Alés-Martínez, J.E., Morales, S., Fernández Abad, M., Sánchez-Rovira, P., Salvador Bofill, F.J., Lahuerta, A., García-Sáenz, J.A., Garau Llinas, I., Díaz Redondo, T., Ferrer, N., Carañana, V., López, R., Alonso Soler, S.E., Bermejo, B., de la Haba, J., Zamora, P., Balmana, J., López-Miranda, E., Cortés, J., Llombart Cussac, A.

Get full text

384TiPEffectiveness of olaparib plus trastuzumab in HER2[+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study by Alés-Martínez, J E, Morales, S, Fernández Abad, M, Sánchez-Rovira, P, Salvador Bofill, F J, Lahuerta, A, García-Sáenz, J A, Garau Llinas, I, Díaz Redondo, T, Ferrer, N, Carañana, V, López, R, Alonso Soler, S E, Bermejo, B, de la Haba, J, Zamora, P, Balmana, J, López-Miranda, E, Cortés, J, Llombart Cussac, A

“…Abstract Background In the OlympiAD trial the use of poly(adenosine diphosphate–ribose) polymerase inhibitor (PARPi) olaparib resulted in better…”
Get full text

384TiP - Effectiveness of olaparib plus trastuzumab in HER2[+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study by Alés-Martínez, J.E., Morales, S., Fernández Abad, M., Sánchez-Rovira, P., Salvador Bofill, F.J., Lahuerta, A., García-Sáenz, J.A., Garau Llinas, I., Díaz Redondo, T., Ferrer, N., Carañana, V., López, R., Alonso Soler, S.E., Bermejo, B., de la Haba, J., Zamora, P., Balmana, J., López-Miranda, E., Cortés, J., Llombart Cussac, A.

“…In the OlympiAD trial the use of poly(adenosine diphosphate–ribose) polymerase inhibitor (PARPi) olaparib resulted in better progression–free survival (PFS)…”
Get full text